by SignalFactory · February 7, 2022 | 10:39:05 UTC
Pfizer (NYSE: PFE) will publish fourth-quarter and full-year earnings on Tuesday, February 8.
Wall Street forecasts fourth-quarter revenue will more than double to $24.2 billion from $11.7 billion the year before. Adjusted EPS is also expected to more than double year-on-year to $0.87 from $0.42, while reported EPS at the bottom-line is seen soaring to $0.82 from the $0.06 squeezed out last year.
The primary driver of that growth will come from its Covid-19 vaccine, which only started to generate material revenue for Pfizer in 2021. The jab is expected to contribute $12.3 billion of revenue in the fourth quarter compared to only $154 million the year before when it made its first sales. However, estimates are wide-ranging among analysts, coming in as low as $11.2 billion to $15.3 billion, suggesting this will be the key to meeting Wall Street’s wider expectations during the quarter.
Pfizer has said it aimed to sell around 2.3 billion doses of its Covid-19 jab in 2021 as a whole, generating around $36 billion in sales.
The outlook for its Covid-19 vaccine in 2022 will be under focus. The last update from Pfizer said it was expecting sales to fall to around $31 billion this year, but this could change considering analyst forecasts range from as low as $29 billion to as high as $40 billion.
Another potential catalyst for Pfizer in 2022 is PAXLOVID, it’s a breakthrough oral treatment for Covid-19 that has shown it can reduce the risk of hospitalization or death by 89% if taken within three days of the onset of symptoms, or 88% within five days. The drug was given emergency use authorization in the US in December and has been given the green light in several other countries since then. Pfizer has said it is aiming to produce up to 120 million courses of treatment in 2022 but has not outlined financial forecasts. It has already agreed to supply 20 million of those doses to the US government, with the first 10 million to be delivered by the end of June and the other 10 million by the end of September. The UK has ordered 2.75 million doses for this year and the EU is likely to follow considering regulators gave the drug conditional marketing authorization just a week ago.
Analysts have currently penciled in $21.2 billion in PAXLOVID sales in 2022, but again forecasts are wide-ranging from $16 billion to $30 billion. One reason for that may be a dispute over what average price Pfizer will be able to charge. The US government has said it would pay $5.29 billion for the first 10 million doses, implying a price of around $529 per course. However, the middle of analyst expectations for the 120 million doses implies a much lower price closer to $177.
Meanwhile, away from Covid-19, the rest of its portfolio is set to have generated just over $23.0 billion in revenue during 2021, according to consensus figures from Bloomberg.
Analysts expect sales of blood clot-preventer Eliquis to climb over 10% from last year while its rare disease drug Vyndaqel is forecast to see a 30% jump. That is anticipated to be countered by lower revenue from its Prevnar-13 vaccine, as well as ankylosing spondylitis therapy Xeljanz, cancer medicine Xalkori, and arthritis treatment Enbrel.
Pfizer Long (Buy) Enter at: 54.07 T.P_1: 58.47 T.P_2: 61.67 T.P_3: 65.99 T.P_4: 69.19 T.P_5: 72.18 S.L: 50.28
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.